Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.

Last updated: October 19, 2020
Sponsor: Noven Pharmaceuticals, Inc.
Overall Status: Completed

Phase

3

Condition

Tourette's Syndrome

Psychosis

Mood Disorders

Treatment

N/A

Clinical Study ID

NCT02876900
HP-3070-GL-04
  • Ages > 18
  • All Genders

Study Summary

This study is designed to evaluate efficacy and safety of HP-3070 compared with placebo transdermal patch in subjects diagnosed with schizophrenia.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Current diagnosis of schizophrenia.

  • Subject has PANSS total score ≥80, AND score of 4 or more in at least 2 of thefollowing PANSS items at Screening and at Baseline: conceptual disorganizationdelusions; hallucinatory behavior; unusual thought content.

  • Subjects must be able to wear a transdermal patch for 24 hours.

Exclusion

Exclusion Criteria:

  • Subject has been diagnosed with schizophrenia less than 6 months prior to ScreeningVisit.

  • Subject has received within 90 days of Screening Visit: electroconvulsive therapy;transcranial magnetic stimulation; vagal nerve stimulation; or other brain stimulationtreatments

  • Subject has experienced acute depressive symptoms within 30 days prior to ScreeningVisit that requires treatment with an antidepressant, as determined by theInvestigator.

  • Currently taking clozapine for the treatment of schizophrenia.

  • Has hypothyroidism or hyperthyroidism.

  • Subject is currently being treated with insulin for diabetes.

  • Subject has epilepsy or history of seizures.

  • Positive urine pregnancy test.

Study Design

Total Participants: 617
Study Start date:
August 01, 2016
Estimated Completion Date:
June 30, 2018

Study Description

This is a Phase 3, randomized, double-blind, placebo-controlled, in-patient, efficacy, and safety study to evaluate HP-3070 for the treatment of schizophrenia.

This study is designed to evaluate efficacy and safety of HP-3070 compared with placebo transdermal patch in subjects diagnosed with schizophrenia, who are in an acute exacerbation and to assess the impacts of covariates on asenapine exposure as delivered in a patch formulation, using a population-based approach.

Connect with a study center

  • Noven Pharmaceuticals, Inc.

    Jersey City, New Jersey 07310
    United States

    Site Not Available

  • Noven Pharmaceuticals, Inc.

    New York, New York 10118
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.